Gilead Sciences Inc. (NASDAQ:GILD) finished Thursday with an addition of $0.69 to close at $85.26, an upside of 0.82 percent. An average of 3,772,020 shares of common stock have been traded in the last five days. There was a fall of -$0.01 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 7,717,690 shares traded, while the 50-day average volume stands at 8,463,780.
GILD stock has decreased by -0.58% in the last month. The company shares reached their 1-month lowest point of $81.81 on 12/20/22. With the stock rallying to its 52-week high on 12/13/22, shares of the company touched a low of $57.17 and a high of $89.74 in 52 weeks. It has reached a new high 18 times so far this year and achieved 17.42% or $12.65 in price. In spite of this, the price is down -4.99% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
GILD stock investors should be aware that Gilead Sciences Inc. (GILD) stock had its last reported insider trading activity 51 days ago on Nov 09. In this transaction, the insider spent $535,736. SVP, Controller & CAO, Wilfong Diane E., disposed of 16,255 shares at a price of $79.25 on Nov 01. The insider now owns more than $1,288,209 worth of shares. Prior to that, EVP,Corp Affairs & Gen Counsel Pletcher Brett A went on to Sale 3,634 shares at $58.24 each on Mar 11. An amount of $211,644 was transacted.
Gilead Sciences Inc. (GILD) has a trailing price-to-earnings (P/E) ratio of 32.25. The stock’s beta is 0.47. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.97, the price-to-book (PB) ratio at 5.08, and the price-to-cash flow ratio at 20.23.
The company has a payout ratio of 109.20%. The company’s most recent quarterly dividend payment was $0.73 a share, without any change from last year. Its latest increase dividend $0.02 reported on Tuesday February 1 2022.
The quick ratio of Gilead Sciences Inc. for the three months ended September 29 was 1.20, and the current ratio was 1.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.09 and a total debt to equity ratio of 1.20 for the quarter ending September 29. Its gross profit as reported stood at $20.7 billion compared to revenue of $27.3 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Gilead Sciences Inc.’s return on assets was 5.20%.
For the three-month period that ended September 29, Gilead Sciences Inc. had $961.0 million in cash and short-term investments compared to $22.95 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $1.79 billion in the quarter, while revenues of $1.14 billion were shrunk -44.89%. The analyst consensus anticipated Gilead Sciences Inc.’s latest quarter earnings to come in at $1.43 per share, but it turned out to be $1.9, a 32.90% surprise. For the quarter, EBITDA amounted to $3.36 billion. Shareholders own equity worth $1.25 billion.
From a technical analysis perspective, let’s take a brief look at Gilead Sciences Inc. (GILD) price momentum. RSI 9-day as of the close on 29 December was 44.97%, suggesting the stock is Neutral, with historical volatility in this time frame at 12.23%.
As of today, GILD’s price is $84.97 -0.01% or -$0.01 from its 5-day moving average. GILD is currently trading -2.93% lower than its 20-day SMA and +38.41% higher than its 100-day SMA. However, the stock’s current price level is +27.50% above the SMA50 and +46.19% above the SMA200.
The stochastic %K and %D were 39.55% and 38.38%, respectively, and the average true range (ATR) was 1.57. With the 14-day stochastic at 43.51% and the average true range at 1.67, the RSI (14) stands at 51.19%. The stock has reached -0.40 on the 9-day MACD Oscillator while the 14-day reading was at -1.36.
The consensus rating for Gilead Sciences Inc. (GILD) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell GILD, while 17 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 13 others rate it as a “buy”.
What is GILD’s price target for the next 12 months?
Analysts predict a range of price targets between $69.00 and $105.00, with a median target of $87.00. Taking a look at these predictions, the average price target given by analysts for Gilead Sciences Inc. (GILD) stock is $85.36.